skip to content

Clinical Trials

MainTitle

Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women

This study has been withdrawn
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)


Information provided by (Responsible Party)
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier
NCT00000809

First received: November 2, 1999
Last updated: May 16, 2012
Last Verified: May 2012
History of Changes
Purpose

Purpose

The purpose of this study is to test the safety and effectiveness of two different formulations of an HIV vaccine in infants born to HIV-infected women.

Condition Intervention Phase
HIV Infections
HIV Seronegativity

Biological : Aluminum hydroxide
Biological : QS-21
Biological : MN rsgp120/HIV-1
Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Prevention
Official Title: A Phase I Trial of the Safety and Immunogenicity of MN rsgp120/HIV-1 With the Adjuvants QS-21 and Alum Compared to MN rsgp120/HIV-1 and QS-21 in Infants Born to HIV-Infected Women

Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Enrollment: 0

Eligibility

Eligibility

Ages Eligible for Study: up to 3 Days  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: Yes  

Criteria

Inclusion Criteria
Infants may be eligible for this study if they:

  • Are 1 to 3 days old.

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000809

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)
More Information

More Information


Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)  
ClinicalTrials.gov Identifier: NCT00000809   History of Changes  
Other Study ID Numbers: ACTG 279  
  11255  
Study First Received: November 2, 1999  
Last Updated: May 16, 2012  

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):

HIV Preventive Vaccine
HIV Therapeutic Vaccine

Additional relevant MeSH terms:
HIV Infections
Vaccines
Aluminum Hydroxide
QS 21

ClinicalTrials.gov processed this data on October 17, 2017
This information is provided by ClinicalTrials.gov.